Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07515924 | Oral Gallium Maltolate for Recurrent Glioblastoma | not yet recruiting | Early Phase 1 | 8 | Medical College of WisconsinOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07830238 | SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 28 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07784985 |
| A Study of NST-628 in Recurrent Grade 4 Glioma |
| not yet recruiting |
| Early Phase 1 |
| 12 |
| Nader SanaiOTHER |
| 1 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Grit BiotechnologyINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer(TIDE) | not yet recruiting | Early Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07802756 | Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Early Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07609225 | Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy | not yet recruiting | Early Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07790939 | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer | not yet recruiting | Early Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | not yet recruiting | Early Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Aug 26, 2026 | clinicaltrials |
| NCT07778979 | Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas | not yet recruiting | Early Phase 1 | 20 | University of Alabama at BirminghamOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07615270 | A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement | not yet recruiting | Early Phase 1 | 5 | Stanford UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05676489 | MeFAMP for Imaging System A Amino Acid Transport in Primary and Metastatic Brain Tumors | not yet recruiting | Early Phase 1 | 28 | University of Alabama at BirminghamOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07741565 | Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) | not yet recruiting | Early Phase 1 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) | not yet recruiting | Early Phase 1 | 22 | Shambavi RichardOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07168785 | [18F]-AraG PET Imaging in LA HNSCC | not yet recruiting | Early Phase 1 | 5 | Indiana UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07712770 | Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma(PRECISE) | not yet recruiting | Early Phase 1 | 12 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | not yet recruiting | Early Phase 1 | 6 | Royan InstituteOTHER_GOV | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07700121 | PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma(PICSTAT) | not yet recruiting | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia(R/R AL) | not yet recruiting | Early Phase 1 | 18 | Zhujiang HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07670260 | GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma | not yet recruiting | Early Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07662200 | A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy(SPARROW-GC) | not yet recruiting | Early Phase 1 | 10 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07007325 | Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)(PASSIFLORE) | not yet recruiting | Early Phase 1 | 15 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07628595 | Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | Early Phase 1 | 19 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639970 | Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | not yet recruiting | Early Phase 1 | 20 | Hua PangOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT07631299 | Nebulized AER101 in Pre-op NSCLC(AER101) | not yet recruiting | Early Phase 1 | 5 | University of OklahomaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07586709 | In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms | not yet recruiting | Early Phase 1 | 18 | Liping DouOTHER | 0 | May 14, 2026 | clinicaltrials |
| NCT07584850 | Evaluation of GI001 for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Early Phase 1 | 9 | Ruijin HospitalOTHER | 0 | May 13, 2026 | clinicaltrials |
| NCT07568366 | AI in Endoscopic Transsphenoidal Surgery | not yet recruiting | Early Phase 1 | 30 | University College, LondonOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07563543 | RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas | not yet recruiting | Early Phase 1 | 10 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT05728879 | Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution | not yet recruiting | Early Phase 1 | 30 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563023 | Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine | not yet recruiting | Early Phase 1 | 6 | West China HospitalOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07546630 | Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy of Relapsed/Refractory B-Cell Lymphoma | not yet recruiting | Early Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT07553767 | Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection | not yet recruiting | Early Phase 1 | 156 | Ningbo No.2 HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07487402 | Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07539233 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. | not yet recruiting | Early Phase 1 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07498595 | TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC | not yet recruiting | Early Phase 1 | 50 | Tianjin Medical University General HospitalOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(CART-BCMA) | not yet recruiting | Early Phase 1 | 3 | Chulalongkorn UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07420010 | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. | not yet recruiting | Early Phase 1 | 24 | Weijia Fang, MDOTHER | 0 | Feb 19, 2026 | clinicaltrials |
| NCT07234721 | SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma(SL4903) | not yet recruiting | Early Phase 1 | 9 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT07399444 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）(LB2505-0001) | not yet recruiting | Early Phase 1 | 38 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07362602 | Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies | not yet recruiting | Early Phase 1 | 47 | The 923rd Hospital of Joint Logistics Support Force of People's Liberation ArmyOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07362732 | Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection | not yet recruiting | Early Phase 1 | 20 | Sichuan UniversityOTHER | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07358195 | Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation | not yet recruiting | Early Phase 1 | 3 | Massachusetts General HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(IASO104) | not yet recruiting | Early Phase 1 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07352345 | Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 150 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07335094 | A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy | not yet recruiting | Early Phase 1 | 60 | Zhujiang HospitalOTHER | 0 | Jan 12, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials